[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-neuropathic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-neuropathic-pain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,69,98,120,143,169,197,225],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100641691","aitbs-and-rtms-in-neuropathic-pain-and-prediction-of-response-100641691",false,"NCT07650526","aiTBS and rTMS in Neuropathic Pain and Prediction of Response","A Double-blind, Randomized, Sham-controlled Crossover Trial Comparing the Analgesic Effects of Accelerated Intermittent Theta Burst Stimulation (aiTBS) and Classical High-frequency rTMS Targeting the Motor Cortex in Chronic Neuropathic Pain, and Prediction of Response.","TRIPP","Inclusion Criteria:\n\n1. Age over 18 years and less than 80 years\n2. Average pain intensity ≥ 4\u002F10 on the numerical scale of the Brief Pain Inventory at screening and randomization\n3. Pain present for at least 4 days per week\n4. Persistent pain for at least 6 months\n5. Stable pharmacological treatment for pain for at least 1 month prior to the study.\n6. Peripheral or central neuropathic pain (postherpetic neuralgia, painful neuropathies, nerve lesions, radiculopathy, trigeminal neuralgia, stabilized multiple sclerosis, spinal cord lesion or stroke) fulfilling criteria for probable or definite neuropathic pain; and scoring ≥ 4 out of 10 on the DN4 questionnaire\n7. Informed consent\n8. Patients who can be followed for the whole duration of the study\n9. Patients affiliated to social security in France\n\nExclusion Criteria:\n\n1. Ongoing litigation\n2. Contraindication to rTMS :\n\n   * implanted electronic devices and\u002For conductive objects near the coil: patients with an active implanted device activated or controlled by physiological signals (e.g. pacemakers, implanted cardioverter defibrillators \\[ICD\\], vagus nerve stimulators \\[VNS\\] and portable cardioverter defibrillators \\[WCD\\], ocular implants, deep 16 brain stimulation, drug chambers\u002Fpumps, intracardiac leads) even if the device has been removed.\n   * Non-removable metal objects near the coil: Patients with a conductive implant, ferromagnetic or made of any other metal sensitive to magnetic fields, in the head or at a distance of less than 30 cm from the coil (e.g. cochlear implant, implanted electrodes\u002Fpacemakers, aneurysm clips or coils, stents and bullet fragments).\n3. Current drug or psychoactive substance abuse (DSM V)\n4. Pregnancy or lactation\n5. Epilepsia or past epilepsia\n6. Progressive unsable pathology (eg cancer)\n7. Current psychosis according to DSM V criteria\n8. Presence of other pain more severe than that justifying inclusion\n9. Lack of correct completion of pain self-assessment diaries between inclusion and randomisation (at least 4 weekly pain scores over 7 days),\n10. Subject unable to understand informed consent, under guardianship or curatorship\n11. Patients participating in another research protocol within 30 days prior to inclusion.\n12. Patient who has already received a treatment with rTMS","ALL","18 Years","80 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study evaluates the analgesic benefit of two non-invasive brain stimulation techniques: high frequency repetitive transcranial magnetic stimulation (rTMS) and accelerated intermittent theta burst stimulation (aiTBS) - compared to sham stimulation, in patients with chronic neuropathic pain lasting at least 6 months.\n\nTranscranial magnetic stimulation, which is delivered by a coil positioned on the scalp over the motor cortex, generates a low-intensity, submotor-threshold electromagnetic field that noninvasively activates targeted brain regions involved in pain perception. The procedure is painless and non-invasive. Sham stimulation uses the inactive face of the same coil and produces an identical sound, ensuring that neither patients nor investigators know which stimulation is being delivered.\n\nConventional rTMS has demonstrated moderate analgesic efficacy in neuropathic pain, but its effect is delayed and requires at least 5 treatment sessions. iTBS delivers the same total stimulation dose in a much shorter time (approximately 8 minutes per session versus 30 minutes for conventional rTMS) and enables accelerated protocols with multiple sessions per day, which have shown promising results in depression.\n\nThis study compares aiTBS, rTMS and sham by a randomized controlled trial (RCT) with a crossover design: participants are randomized in a 2:1 ratio to receive either active stimulation (both techniques in sequence) or sham stimulation (both techniques in sequence). Each treatment phase consists of either 5 consecutive daily rTMS sessions or 5 aiTBS sessions delivered on a single day (with a 45-min pause between sessions). The cross-over will take place after a 4 to 6-week washout period between the two active or sham treatments. The total study duration per participant is from 10 to 12 weeks, with 11-12 in-person visits.\n\nAssessments include self-reported pain diaries numeric pain rating scale (NPRS), validated pain, psychosocial, and quality-of-life questionnaires, resting-state Electroencephalography (EEG) recordings, and transcranial magnetic stimulation (TMS) based measures of intracortical excitability and inhibition. The exploratory aim is to identify neurophysiological and clinical predictors of treatment response, to better personalize the treatment in chronic pain population.",[28],"Chronic Neuropathic Pain","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":22},"2026-09",{"date":37,"type":22},"2028-09",{"name":39,"class":40},"Hospital Ambroise Paré Paris","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100591478","phase-1-safety-and-tolerability-study-of-st-503-for-refractory-pain-due-to-peripheral-neuropathy-small-fiber-predominant-sfn-100591478","NCT06980948","Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)","A Multicenter Phase 1 \u002F 2 Double-blind, Randomized, Sham-controlled Dose Escalation Study to Determine Safety and Tolerability of Single Dose Intrathecal ST-503 Gene Therapy for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)","Inclusion Criteria\n\n1. Diagnostic characterization of Small Fiber Neuropathy (SFN) according to the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) criteria.\n2. Medical record documentation that pain is refractory to 2 of 3 categories of first line medical therapy for at ≥ 6 months prior to screening.\n3. Serum sample negative for pre-existing anti-AAV9 antibodies determined by assay detection limit\n\nExclusion Criteria\n\n1. Drug- and alcohol-related:\n\n   1. Persons using opioid analgesics for under 3 months or persons who are not on a stable dose of opioids; if on a stable dose, the dose may decrease over the course of the study but should not be increased.\n   2. History of known alcohol abuse, opioid analgesic abuse, or illicit drug abuse within 2 years of Screening.\n   3. Positive urine test for drugs of abuse (including opiates, benzodiazepines, amphetamines, cocaine, barbiturates, and phencyclidine) without prescription and investigator approval, at Screening and Day -1.\n   4. Use of cannabinoids is not permitted.\n2. Persons with Fabry's disease, with erythromelalgia, with peripheral neuropathies due to alcohol or drug toxicity, or with diagnosed channelopathies\n3. Procedure-related:\n\n   1. Contraindications to LP, general anesthesia or sedation\n   2. Any medical disorders that, in the opinion of the Investigator, could interfere with LP including but not limited to evidence for a pressure gradient between supratentorial and infratentorial compartments, Arnold-Chiari malformation, bleeding diathesis, clinically significant coagulopathy, thrombocytopenia, increased intracranial pressure, or spine disease or past surgical procedures involving the spine\n4. Infectious disease-related:\n\n   1. Active viral infection or bacterial\n   2. A severe infection (e.g., pneumonia, septicemia, central nervous system infections \\[e.g., meningitis, encephalitis\\]) within 12 weeks prior to Screening\n5. Hepatic disease- and hepatotoxic medication-related:\n\n   1. Presence of clinically relevant liver disease\n   2. Hepatic dysfunction as indicated by one or more of the following: i. Albumin ≤ 3.5 g\u002FdL ii. Total bilirubin \\> 1.5 x ULN and direct bilirubin ≥0.5 mg\u002FdL iii. Alkaline phosphatase (ALP) \\> 2 x ULN iv. Alanine transaminase (ALT) or aspartate transaminase (AST) \\> 1.5 x ULN\n   3. Hepatotoxic medications should be avoided during the study period including acetaminophen exceeding 4 gm\u002Fday unless essential to patient's treatment, approved by investigator, and hepatic dysfunction is not identified\n   4. Hepatotoxic supplement use during the study period\n6. Cancer-related:\n\n   a. History of cancer, including B-cell cancers, within 5 years of Screening\n\n   i. Exceptions to this exclusion are fully excised non-melanoma skin cancers, non-metastatic prostate cancer, and fully treated ductal carcinoma in situ of the breast, provided subject has been stable for at least 6 months\n\n   b. Previous autologous or allogeneic bone marrow transplant, peripheral stem cell transplant or solid organ transplantation\n7. Previously received gene or cellular therapy",{"count":50,"type":22},27,[52,53],"PHASE1","PHASE2","This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).\n\nST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).",[28],[57],"Small Fiber Neuropathy","2026-05-28",{"date":60,"type":33},"2026-06-01",{"date":62,"type":33},"2025-12-04",{"date":64,"type":22},"2028-07",{"name":66,"class":67},"Sangamo Therapeutics","INDUSTRY",11,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100480588","phase-4-low-dose-naltrexone-for-pain-in-patients-with-hiv-100480588","NCT05537935","Low Dose Naltrexone for Pain in Patients With HIV","Low Dose Naltrexone (LDN) for the Treatment of Chronic Neuropathic Pain in Patients With Human Immunodeficiency Virus (HIV), a Prospective, Pragmatic, Open Label Clinical Trial","Inclusion Criteria:\n\n* Age 18-75, male and female\n* HIV infection with a viral load of \\\u003C 1000 copies\u002Fml for the past 12 months. (That is the viral load below which, according to the 2018 American College of Obstetricians and Gynecologists (ACOG) Committee Opinion, there is no thought of a significant risk of HIV transmission from the mother to the fetus with vaginal delivery. This was thought to be a reasonable cut-off for inclusion in this study.)\n* Diagnosis of neuropathic pain (pain that is associated with a lesion or disease involving the somatosensory nervous system, e.g., painful neuropathy, radicular pain, complex regional pain syndrome, nerve-related pain following spine surgery, etc.) using the neuropathic pain screening tool, painDETECT17, as part of the neuropathic pain screen.\n* Pain score \\> 4\u002F10 on average on the NPRS lasting \\> 3 months (chronic pain)\n* Capable of informed consent and willing to comply with the study requirements\n* Fluent English-speaking\n\nExclusion Criteria:\n\n* Allergy to naltrexone (not applicable to the control group)\n* Current use of any opioids, up to 10 days before the start of the study (not applicable to the control group)\n* Pregnant women\n* Nursing mothers and women of childbearing potential not using contraception known to be highly effective (not applicable for the control group). Highly effective contraception methods include a combination of any two of the following during the 12-week study period:\n\n  1. Use of oral, injected, or implanted hormonal methods of contraception or;\n  2. Placement of an intrauterine device (IUD) or intrauterine system (IUS);\n  3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical \u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fvaginal suppository;\n  4. Total abstinence;\n  5. Male\u002Ffemale sterilization.\n* Bipolar disorder, schizophrenia, poorly controlled anxiety or depression\n* Diagnosis of liver disease, e.g. cirrhosis\n* Current diagnosis of either chronic kidney disease or acute kidney injury and\u002For a GFR \\\u003C45 at baseline\n* Acute viral hepatitis A, B, C\n* Patients who self-report as having tested positive for COVID-19 or have been diagnosed with another viral illness within the past ten days.\n* Patients with a known or suspected diagnosis of long-term COVID\n* Active drug or alcohol use disorder\n* People who may require opioid therapy during the duration of the study, e.g. upcoming surgery\n* Transportation issues interfering with return study visits (NA for the control group)\n* Adults unable to consent\n* Prisoners","75 Years",{"count":78,"type":22},60,[80],"PHASE4","The increased life expectancy of Patients Living With HIV\u002FAIDS (PLWHA) has increased the need for therapies for chronic conditions, such as chronic pain. Pain in the HIV population is often refractory and ends up being treated with chronic opioids, which are associated with adverse effects, including hyperalgesia, constipation, and risk of overdose. Naltrexone is an opioid antagonist used in the treatment of alcohol and opioid use disorders. Low Dose Naltrexone (LDN), naltrexone at a much lower dose, is thought to be an immune modulator and has been associated with an increased CD4 count in PLWHA. Repurposing this medication is relatively inexpensive and has the potential to expand access to treatment for a painful condition experienced in PLWHA. While there are many case reports on the efficacy of LDN in symptom reduction, there are only a small number of clinical trials that specifically examine pain and symptom relief.\n\nThis study will include patients who are not completely virologically controlled and will monitor the CD4 counts drawn as a part of routine care. If the CD4 count improves with LDN and with reduced symptoms, this could be a significant improvement in HIV therapy for symptom control. There have been studies showing cytokine reduction in fibromyalgia patients but they did not investigate the correlation with cytokines and pain relief. This study involves repurposing a drug used for substance use disorder to a medication with the potential to treat pain and improve symptoms for PLWHA.",[83,28],"Human Immunodeficiency Virus",[85,86,87],"Low dose Naltrexone","Naltrexone","Pain","2026-04-06",{"date":90,"type":33},"2026-04-09",{"date":92,"type":33},"2023-04-28",{"date":94,"type":22},"2027-06-30",{"name":96,"class":40},"Emory University",3,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":41},"100604787","evaluation-of-the-efficacy-of-stns-with-fast-and-multiwave-in-patients-with-refractory-chronic-neuropathic-pain-100604787","NCT07154056","Evaluation of the Efficacy of STNS With FAST and MULTIWAVE in Patients With Refractory Chronic Neuropathic Pain","Prospective, Longitudinal, Single-arm Interventional Study Evaluating the Efficacy of Spinal Transforaminal NeuroStimulation (STNS) With FAST and MULTIWAVE Stimulation in Patients With Refractory Chronic Neuropathic Pain","FORASTIM","Inclusion Criteria:\n\n* Subject has ≥ 18 years and ≤ 80 years\n* Subject has a global Visual Analogic Scale ≥ 5\n* Subject has non-cancer pain with a significant neuropathic component for at least 6 months.\n* Subject has stable pain for at least 30 days\n* Pain medication(s) dosage(s) is\u002Fare stable for at least 30 days\n* Subject is eligible for Spinal Transforaminal NeuroStimulation after a pre-implantation assessment by a multidisciplinary team, as described by the French National Authority for Health (Haute Autorité de Santé)\n* Subject understands and accepts the constraints of the study and is able to use the equipment.\n* Patient is covered by French national health insurance.\n* Subject has given written consent to the study after having received clear and complete information.\n\nNon-inclusion Criteria:\n\n* Subject has a coagulation disorder\n* Subject is or has been treated with SCS, subcutaneous or peripheral nerve stimulation, an intrathecal drug delivery system\n* Subject has had corticosteroid therapy within the past 30 days\n* Subject has had radiofrequency therapy within the past 3 months\n* Subject has been diagnosed with cancer in the past 2 years\n* Subject has had a spinal surgery within the past 6 months\n* Simultaneous participation to any interventional study on health product or any study able to interfere with the current study endpoints.\n* Subject has at least one of brain MRI contraindications such as : intracranial clips \u002FVascular clips\u002FPace maker\u002FHeart battery, Defibrillator, Implanted Holter (REVEAL type), Neuro-stimulator not compatible with 1.5 T MRI\u002FStents\u002F Coils\u002FCardiac valves (heart)\u002F Shunt valve\u002FImplanted injection pump\u002FCochlear implants\u002FImplantable chamber (PAC)\u002FIntracorporeal metal shards\u002F metallic foreign bodies, the location and the presence of implanted neurostimulation components that are not listed as MRI Conditional, cardiac implantable electronic device, metallic intraocular foreign bodies, cochlear implants, drug infusion pumps, catheters with metallic components, cerebral artery aneurysm clips, magnetic dental implants, tissue expander, artificial limb, hearing aid, piercing.\n* Subjects requiring closer protection, i.e. minors, subjects deprived of their freedom by a court or administrative decision, subjects admitted to a health or social welfare establishment, major subjects under legal protection, and finally patients in an emergency setting\n* Pregnant or breastfeeding women, women at age to procreate and not using effective contraception.",{"count":107,"type":22},17,[25],"The goal of the study is to demonstrate Spinal Transforaminal NeuroStimulation effectiveness with FAST and other waveforms \u002F combinations to relief neuropathic peripheral pain in chronic neuropathic pain patients, at low risk and low energy consumption.",[28],"2026-02-11",{"date":113,"type":33},"2026-02-17",{"date":115,"type":33},"2026-02-10",{"date":117,"type":22},"2027-10-10",{"name":119,"class":40},"Poitiers University Hospital",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":41},"100616132","phase-2-ecstasy-to-alleviate-severe-chronic-neuropathic-pain-trial-100616132","NCT07301632","Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial","Ecstasy to Alleviate SEvere Chronic Neuropathic Pain (EASE Pain) Trial: A Randomized Controlled Pilot Trial","EASEPain","Inclusion Criteria:\n\n* Consenting adults 18 years and older.\n* Diagnosis of chronic neuropathic pain (greater than 3 months in duration) by a clinician with specialized training in chronic pain, confirmed with the standardized Leeds Assessment of Neuropathic Symptoms and Signs questionnaire.\n* Suffering from moderate-to-severe pain as defined by\n* Baseline Patient Reported Outcomes Measurement System - Pain Interference (PROMIS-PI) score of greater than or equal to 60\n* An average pain intensity of greater than or equal to 5 on a 0-10 numeric rating scale,43\n* Treatment-refractory pain as defined by a failure of ≥2 medications recommended in the Canadian consensus guidelines on the management of CNP to generate self-reported meaningful improvement in symptoms.\n* For participants of childbearing potential, use of a highly effective or double-barrier methods of contraception. Abstinence is acceptable if it is the preferred and usual lifestyle of the participant.\n* Sufficient English skills to participate in psychotherapy.\n\nExclusion Criteria:\n\n* Past or current history of a psychotic disorder, mania, hypomania, bipolarity, current suicidal ideation, stimulant use disorder (i.e., cocaine, amphetamine, methamphetamine, MDMA, methylphenidate (Ritalin), etc , and any other substance use disorder within the past 12 months assessed by history and confirmed the Mini-International Neuropsychiatric Interview \\[MINI\\]. Other secondary psychiatric comorbidities (e.g., anxiety disorders, trauma related disorders, other personality disorders. etc.) will not be excluded\n* Participants with a history of suicide attempts are not excluded unless a significant risk of suicidal behavior is present at the time of screening as determined by the CRSS (Columbia suicide rating scale)\n* History of prior MDMA use (excluded to maintain blinding integrity)\n* Long QT syndrome, measured by an ECG with a QTc more than 450 ms for males, and 470 ms for females.\n* Presence of a relative or absolute contraindication to MDMA or Methylphenidate:\n* Pre-existing cardiovascular disorders evidenced in clinical records or disclosed on patient self-report, such as: uncontrolled hypertension (sustained blood pressure ≥160\u002F100 mmHg), angina (ongoing angina at rest, recent hospitalization for acute coronary syndrome within the past 3 months, or a history of revascularization (e.g., stenting or bypass surgery) within the past 6 months), arterial occlusive disease; heart failure, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction (within the past 6 months), potentially life-threatening arrhythmias (new-onset within the last 3 months), arrhythmias causing hemodynamic instability (SBP \\\u003C 90 mm Hg), or requiring urgent intervention (e.g., atrial fibrillation with rapid ventricular response or ventricular tachycardia), channelopathies, aneurysmal vascular disease (e.g., thoracic and\u002For abdominal aorta, intracranial, and peripheral arterial vessels), advanced arteriosclerosis\n* Cerebrovascular conditions: acute stroke or recent history of intracerebral hemorrhage (ischemic or hemorrhagic stroke occurring within the past 6 months)\n* Conditions at risk of elevation of blood pressure and increase heart rate, such as glaucoma, tension, agitation, thyrotoxicosis, pheochromocytoma\n* Motor tics and\u002For family history or diagnosis of Tourette's syndrome\n* Moderate to severe chronic kidney disease or kidney failure, such as requiring dialysis, significant treatment adjustments for kidney function, or regular nephrologist follow-up)\n* Moderate to severe liver disease, such as cirrhosis, a history of significant jaundice unrelated to temporary illness, or any liver condition requiring regular monitoring by a specialist).\n* Current treatment with selective serotonin reuptake inhibitors (SSRI's) and serotonin-norepinephrine reuptake inhibitors (SNRI's), tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans) and 5-HT3 receptor antagonist antiemetics (risk of Serotonin Syndrome)\n* Hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption (methylphenidate contains lactose)\n* Seizure disorders\n* Pregnancy, or breastfeeding\n* Known hypersensitivity to study drugs or any study drug excipients\n* Medications that interact with study drugs including:\n* Any lifetime history use of any stimulant medication (e.g., Adderall, Vyvanse, Ritalin)\n* Caffeine intake within 24 hours\n* Monoamine oxidase inhibitors (MAOI) within 14 days (e.g. phenelzine, moclobemide, isoniazid, linezolid, phenelzine, harmine) due to risk of hypertensive crisis\n* CYP2D6 substrates and modifiers (such as: buproprion, fluoxetine, paroxetine, duloxetine, mirabegron).\n* Adrenergic agents (e.g. clonidine) risk of sudden death\n* Vasopressor agents (ephedrine pseudoephedrine)\n* Coumarin anticoagulants (e.g., warfarin),\n* Anticonvulsants (e.g., phenobarbital, diphenylhydantoin, primidone)\n* Anti-psychotics and inhibitors of dopamine uptake (e.g. haloperidol, DOPA, tricyclic antidepressants)\n* Concomitant medication that could prolong ECG QT interval (e.g. ondansetron, risperidone, methadone)\n* Selective Serotonin Reuptake Inhibitors (citalopram, sertraline, fluvoxamine, escitalopram)\n* Selective Norepinephrine Uptake Inhibitors (e.g. venlafaxine, duloxetine); Serotonergic Drugs (e.g. dextromethorphan, fentanyl, St. John's Wort, tramadol, 5-hydroxytryptophan); serotonin 5-HT1 receptor agonists (triptans) and 5-HT3 receptor antagonist antiemetics due risk of Serotonin Syndrome which is a potentially life- threatening condition\n* Currently engaged in psychotherapy for CNP (other psychotherapy for non-CNP is allowed).\n* Any other clinically significant medical illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if they take part in the study.",{"count":129,"type":22},40,[53],"This is a Health Canada regulated internal pilot study designed to assess the feasibility, tolerability, and preliminary efficacy of 3, 4-methylenedioxymethamphetamine hydrochloride capsules-AT for chronic neuropathic pain to inform a larger, fully powered multi-center study. This is an interventional, randomized, 2-arm parallel, triple blinded study.\n\nThe total study duration is 2 years.\n\nParticipants will receive preparatory psychotherapy session during week 2 and week 4 followed by a combined single dosing session with psychotherapy during week 6. Integrative psychotherapy will follow at weeks 6, 8, 12, and 16.\n\nFollow up for primary clinical endpoint at week 16; final follow up for secondary clinical endpoint at 16-weeks.\n\nParticipants will be asked to complete adjunctive home psychotherapy in the form of online modules. Data collected will be entered in electronic case report form (REDCap Academic).",[28],[134,28],"3, 4-methylenedioxymethamphetamine hydrochloride",{"date":136,"type":33},"2026-02-13",{"date":138,"type":33},"2026-01-30",{"date":140,"type":22},"2028-12-01",{"name":142,"class":40},"Unity Health Toronto",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":165,"leadSponsor":167,"locationsCount":41},"100573077","phase-3-mechanisms-of-stimulation-for-pain-alleviation-100573077","NCT06741579","Mechanisms of Stimulation for Pain Alleviation","M-SPA","Inclusion criteria for study participants\n\nAdults aged 18 or older with clinically diagnosed unilateral CNP in the lower back, pelvis, or lower extremities, defined (per IASP classification) as persistent or recurrent neuropathic pain caused by a peripheral nerve lesion, history of a plausible nerve trauma, pain onset in temporal relation to the trauma, and pain distribution within the innervation territory of a peripheral nerve (or nerves).14 Negative and positive sensory symptoms or signs must be compatible with the innervation territory of the affected nerve. Can be post-traumatic, post-surgical, nerve compression, nerve ischemia, peripheral nerve injury, painful scar, nerve entrapment, mononeuropathy with or without loss of motor function\n\nPatients enrolled in this study must already have been referred for or have an existing order for PNS therapy (either Nalu or SPR SPRINT), prior to consent and enrollment in this study, as part of their routine medical care. Patients cannot receive a referral for PNS device as part of the study procedures.\n\nPositive response (at least 50% pain relief) to diagnostic nerve block(s) at the suspected site(s) of CNP.\n\nChronic (at least 6 months duration), intractable peripheral neuropathic pain; any nociceptive pain must be less prominent than the neuropathic pian.\n\nFluent in English writing, reading, and speaking\n\nAbility and willingness to complete online assessments\n\nWilliness to refrain from physical activity for at least 7 days post-lead placement.\n\nWillingness to refrain from physical activity or exercise causing muscle and\u002For joint soreness for 48 hours prior to QST, illicit drugs (marijuana) for 12 hours, as-needed (PRN) pain medications (e.g., NSAIDs, acetaminophen, opioids) for 12 hours prior to QST, and alcohol and nicotine on the day of QST prior to testing\\*\n\nExclusion Criteria:\n\nConditions causing inability to complete assessments (education, cognitive ability, mental status, medical status)\n\nActive cancer diagnosis, active malignant neoplasm (metastatic or local) or evidence of paraneoplastic syndrome\n\nPainful polyneuropathy (e.g., metabolic, autoimmune, familial, infectious disease, environmental toxins, treatment with neurotoxic drug)\n\nChronic central neuropathic pain (e.g., spinal cord injury, brain injury, multiple sclerosis)\n\nPeripheral vascular disease\n\nDiabetic neuropathy\n\nAnother pain diagnosis affecting the CNP site that could interfere with study procedures, accurate reporting and\u002For could confound evaluation of study endpoints (e.g., post-herpetic neuralgia)\n\nOther active implantable devices (e.g., implantable cardioverter defibrillator, spinal cord stimulator, dorsal root ganglion stimulator, sacral nerve stimulator, deep brain stimulator, intrathecal pump)\n\nPregnancy, breastfeeding, or planning to conceive\n\nSystemic infection or local infection at the anticipated PNS implant site\n\nImmunocompromised state\n\nCoagulation disorder, bleeding diathesis, platelet dysfunction, active anticoagulation\n\nInterventional procedure and\u002For surgery to treat CNP in the last 30 days (subjects should be enrolled 30 days after last procedure, for prior ablative treatment must be enrolled at least 3 months after last procedure)\n\nUntreated substance use disorder\n\nParticipating in another clinical trial with an active treatment arm\n\nNumbness or loss of sensation at the bilateral thumbnails, peripheral neuropathy in the hands, circulatory or sensory problem in the hands\\*\n\nParticipants with a history of Raynaud's Syndrome\\*\n\nParticipants with SBP ≥150 and\u002For DBP ≥100\\*\n\n\\*QST Inclusion\u002FExclusion Criteria. Participants can still be enrolled iif they have the QST-only exclusionary criteria have the QST-only exclusionary criteria, but QST will be modified based on responses\n\nAdditional Exclusion Criteria for Subjects receiving PET\u002FMRI and PET\u002FCT imaging at Stanford:\n\nPrior radiation exposure of \\>2 rem total within the last 12 months\n\nStandard contraindications that would preclude MRI including pacemakers or other electronic implants, metal foreign objects or fragments in the eye or body, and aneurysm clips.\n\nClaustrophobia\n\nInability to understand and communicate with the investigators to complete the study related questionnaires\n\nFemales with positive pregnancy test.",{"count":151,"type":22},148,[153],"PHASE3","This is a mechanistic randomized controlled trial of patients with chronic neuropathic pain (CNP) in the lower back, pelvis, and lower extremities, randomized to conventional medical management (CMM) or combined CMM and peripheral nerve stimulation therapy (PNS+CMM). Our goal is to compare treatment outcomes and trial response rate across the control and interventional device groups.",[156,157,28],"Chronic Neuropathic Pain in the Low Back and Legs","Peripheral Nerve Stimulation",[159,160],"SPRINT PNS","NALU PNS","2025-09-26",{"date":163,"type":33},"2025-10-02",{"date":161,"type":33},{"date":166,"type":22},"2028-11-01",{"name":168,"class":40},"Stanford University",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":41},"100607335","efficacy-of-repetitive-transcranial-magnetic-stimulation-over-the-primary-cortex-in-patients-with-neuropathic-pain-and-cancer-100607335","NCT07187219","Efficacy of Repetitive Transcranial Magnetic Stimulation Over the Primary Cortex in Patients With Neuropathic Pain and Cancer","Efficacy of Repetitive Transcranial Magnetic Stimulation Over the Primary Cortex in Patients With Neuropathic Pain and Cancer: Cross-over and Placebo-control Study","NeuroCanPain","Inclusion Criteria:\n\n* Patient affiliated to or entitled under a social security scheme\n* Patient who has received informed information about the study and who has co-signed, with the investigator, a consent form to participate in the study.\n* Patient aged 18 to 85 (male or female),\n* Central or peripheral neuropathic pain related to cancer and\u002For its treatment;\n* Chronic pain (present for more than 4 months) whose intensity is greater than or equal to 4\u002F10 on a VAS (Visual Analogue Scale) numerical scale.\n* Pain present on a daily or almost daily basis (at least 4 days a week)\n* Patient not completely relieved by recommended first- and second-line drug treatments for neuropathic pain\n* Stable analgesic treatment (no new treatment or dosage adjustment) for at least one month and will not need to be modified for the duration of the study.\n* Patient can be followed throughout the study.\n* Indication for rTMS of the motor cortex by a neurologist.\n\nExclusion Criteria:\n\n* Accident at work or litigation,\n* Contraindication to rTMS or MRI (treatment with seismotherapy during the previous month; history of cranial trauma; intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulin pump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia).\n* Chronic alcoholism\n* Abuse of drugs or psychoactive substances\n* Neuropathic pain as part of a progressive pathology (e.g. HIV),\n* Presence of other pain of greater intensity than the neuropathic pain leading to inclusion\n* Acute stroke (\\\u003C 3 months)\n* Patient with brain tumour lesions\n* Patient with infectious or metabolic brain lesions\n* Patients with severe or recent cardiac disorders\n* Patients with cognitive impairment\n* Patient unable to understand informed consent,\n* Patients refusing to stop or unable to stop treatments prohibited during the study, such as morphine.\n* Patients participating in another research protocol involving a medicinal product within 30 days prior to inclusion.\n* Patients deprived of their liberty or under legal protection (guardianship, curatorship, safeguard of justice, family habilitation).","85 Years",{"count":78,"type":22},[25],"High-frequency repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex (M1) has shown its efficacy to alleviate pain in patients suffering from refractory neuropathic pain. rTMS is now considered as 3rd-line therapy (by the French Society for the Study and Treatment of Pain) for patient's refractory to drug therapy.\n\nHowever, its efficacy in chronic neuropathic pain related to cancer has not yet been specifically studied, and it therefore remains relatively inaccessible for these patients. This project is a cross-over, double-blinded, and placebo-control study, including 5 sessions of either M1 or \"sham\" rTMS, a wash-out period (8 weeks), followed by 5 sessions of the other stimulation option (I.e., two arms: M1-sham or sham-M1; order randomized between patients). Treatment efficacy will be assessed in comparison to the placebo condition. Primary outcome is the percentage of pain relief between active and sham rTMS. Other variables to describe quality of life, sensory, neuropathic, and mood states as well as resting-state fMRI will be collected before and after treatment.",[182,28],"Cancer",[184,182,185,186,187],"Neuropathic pain","Transcranial magnetic stimulation","Neuromodulation","Pain relief","2025-09-16",{"date":190,"type":33},"2025-09-22",{"date":192,"type":33},"2025-06-13",{"date":194,"type":22},"2029-05",{"name":196,"class":40},"Centre Hospitalier Universitaire de Saint Etienne",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},"100572289","phase-2-psilocybin-for-enhanced-analgesia-in-chronic-neuropathic-pain-100572289","NCT06731335","Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN","PEACE-PAIN","Inclusion Criteria:\n\n* 18-65 years of age\n* Diagnosis of chronic neuropathic pain as determined by a pain specialist\n* Moderate-to-severe neuropathic pain determined by Patient Reported Outcomes Measurement Information System (PROMIS)\n* Previous trials of at least two medications recommended in the Canadian consensus guidelines on the management of neuropathic pain with no self-reported meaningful improvement in symptoms\n* Sufficient command of English to participate in psychotherapy\n* For participants of childbearing potential, use of a highly effective or double-barrier methods of contraception.\n\nExclusion Criteria:\n\n* History of Dextromethorphan addiction or abuse.\n* Enzyme CYP2D6 deficient as shown on the pharmacogenetic test.\n* Underlying psychiatric conditions: lifetime or family history of a primary psychotic disorder, bipolar disorder, borderline personality disorder, paranoid personality disorder, current suicidal ideation, and substance use disorder within the past 12 months as assessed by history and confirmed by the Mini International Neuropsychiatric Interview (MINI)\n* Medications that interact with study drugs\n* Medical condition that is unstable or inadequately controlled, including cardiovascular disease, liver disease, or end-stage renal disease\n* Previous lifetime use of a serotonergic psychedelic drug\n* Nursing or pregnant women.\n* Any other clinically significant medical illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if they take part in the study","65 Years",{"count":21,"type":22},[53],"This is a feasibility study to examine the use of use of Psilocybin (magic mushrooms) to alleviate pain in chronic neuropathic pain.\n\nWhile theoretical mechanisms demonstrate promise, there is no clinical evidence. This vacuum of clinical evidence has been occupied by a \"psychedelic hype bubble\" with media communications touting psychedelics as a 'miracle cures'. The mismatch between evidence and perception creates an urgent need for RCT to fill this significant gap. This trial aims to address this gap by conducting a pilot trial assessing the feasibility, tolerability, and preliminary efficacy of psilocybin for chronic neuropathic pain to inform a future larger, multi-centre study.\n\nThe purpose is to conduct a randomized control double-blinded trial of psilocybin and active placebo (dextromethorphan).\n\nAt this time, the aim of the trial is to recruit 30 participants from St. Michael's Hospital, to learn whether it will be feasible to plan a larger study in the future.",[28,209],"Pain Management",[211,212,213,214,215],"chronic pain","neuropathic pain","psychodelics","psilocybin","chronic neuropathic pain","2025-03-25",{"date":218,"type":33},"2025-03-30",{"date":220,"type":33},"2025-03-05",{"date":222,"type":22},"2026-12",{"name":142,"class":40},2,{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":235,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":41},"100434401","study-of-rtms-analgesic-effect-in-chronic-neuropathic-pain-100434401","NCT04936646","Study of RTMS Analgesic Effect in Chronic Neuropathic Pain,","Randomized Double-blind Study of RTMS Analgesic Effect in Chronic Neuropathic Pain. Comparison Between Three Groups: Motor Cortex Stimulation by the Classic Coil B65, Deeper Stimulation by the Coil B70 and Placebo Stimulation. Analysis of Long-term RTMS-induced Brain Changes Using FMRI.","NEUROSTIM","Inclusion Criteria:\n\n* Patient's written consent\n* Affiliated with social security system\n* Male or female, suffering for more than a year from unilateral refractory neuropathic pain: hemi-body, upper limb, lower limb and facial chronic pain.\n* Patient whose analgesic treatment, is stable for at least 1 month.\n* Patient not responding to conventional treatments\n* Prescreening EVN \\>3\n\nExclusion Criteria:\n\n* History of drug addiction, epilepsy, cranial trauma\n* History of psychiatric disorder\n* Patients previously treated with rTMS\n* Patient with intracranial ferromagnetic material or implanted stimulator\n* New treatment for less than one month\n* Pregnant or Breastfeeding woman\n* Patient who does not understand the study protocol\n* Persons who are protected under the act.",{"count":234,"type":22},45,[25],"The purpose of this study is to compare the analgesic effectiveness of three modes of repetitive Transcranial Magnetic Stimulation (rTMS) in chronic neuropathic pain:\n\n* Classical rTMS stimulation\n* Deeper rTMS stimulation\n* Sham rTMS stimulation",[28],[239,240,241],"rTMS","Chronic neuropathic pain","Repetitive Transcranial Magnetic Stimulation","2024-12-03",{"date":244,"type":33},"2024-12-06",{"date":246,"type":33},"2021-07-16",{"date":248,"type":22},"2025-12-01",{"name":250,"class":40},"University Hospital, Grenoble"]